There is an on-going and dramatic increase in the incidence of autoimmune diseases worldwide.
Factors that are contributing to this increase include stress, high fat diet, sedentary life style, environmental pollution and genetics.
Our Solution: Artificial Intelligence Drug Target Discovery Platform
Current treatments: patients with chronic inflammatory diseases, including ulcerative colitis & Crohn’s Disease are treated with anti-inflammatory agents that temporarily control the symptoms of the disease but also have major toxicities, including increased risk of infections and cancers.
Our approach: Athos has developed an innovative computational process based on machine learning algorithms that identifies novel and safe drug/gene targets for individual patients.
Individual Patient Omic Data
Autoimmune Disease Drug Development Platform
small compounds targeting immune cells – epithelial integrity – microbiome interactome
T-regulatory cells (Tregs) represent a small subpopulation of immune cells that have the ability to activate anti-inflammatory molecules, while simultaneously blocking pro-inflammatory genes. Athos’ chemistry platform has been developed and optimized to identify novel compounds that have the ability to activate Tregs. There is extensive scientific rationale supporting the therapeutic potential of Treg cell population in different inflammatory diseases, including Inflammatory Bowel Diseases and Lupus.
Autoimmune and inflammatory diseases such as Ulcerative Colitis and Crohn’s Disease have a defect in the intestinal epithelial barrier, leading to the development of a “leaky gut.” Leaky gut allows bacteria and other microbes to enter the mucosa and activated inflammatory cells. The Athos inflammatory bowel disease lead compounds were designed to pharmacologically restore the normal intestinal barrier, repair the abnormal leaky gut, reduce inflammation, and induce mucosal healing.